"MAT" (medication-assisted treatment, sometimes now called MOUD — medications for opioid use disorder) refers to three FDA-approved medications. They're often discussed as one category, but they work differently enough that the choice between them is a real clinical decision, not an interchangeable detail.
The three options, compared
| Methadone | Buprenorphine (Suboxone, Subutex) | Naltrexone (Vivitrol) | |
|---|---|---|---|
| How it works | Full opioid agonist — activates opioid receptors fully | Partial agonist — activates receptors partially, with a "ceiling effect" | Opioid antagonist — blocks receptors, produces no opioid effect |
| Where you get it | Only through a certified Opioid Treatment Program (OTP), typically daily in-person dosing (take-home doses earned over time) | Can be prescribed by certified providers, including many primary care and telehealth options — a major access difference | Prescribed by any licensed provider; monthly injectable or daily pill form |
| Requires opioid-free period first? | No | Usually yes — starting too soon while opioids are active can trigger precipitated withdrawal | Yes — typically 7–10 days opioid-free before starting, or it can trigger severe withdrawal |
| Overdose risk if misused | Higher — full agonist, dosing errors are more dangerous | Lower — ceiling effect limits respiratory depression risk | None from the medication itself — it has no opioid activity |
Why access differs so much
Methadone's daily-clinic-visit requirement traces back to historical concerns about diversion and its narrower safety margin as a full agonist — it's effective, and for some people the daily structure itself is stabilizing, but the logistics are real, especially for people working, caring for family, or without reliable transportation. Buprenorphine's safety profile allowed a different regulatory path, which is why it's available through office-based providers and increasingly via telehealth — a significant access advantage for many people. Naltrexone requires no controlled-substance prescribing restrictions at all, but the requirement to be fully opioid-free before starting is a real practical hurdle for some.
There's no single "best" option
The right choice depends on someone's specific situation: how long they've used, prior treatment history, access to a certified OTP versus a prescriber, work and family logistics, and personal preference all matter. All three medications are associated with meaningfully better outcomes — reduced overdose risk, reduced illicit opioid use, better treatment retention — compared to no medication at all, which is the more important takeaway than which specific one is "best."
A common misconception worth addressing directly: MAT is not "replacing one addiction with another." These medications, taken as prescribed, don't produce the impairment or escalating use pattern that defines addiction — they stabilize brain chemistry disrupted by opioid use disorder, similar to how insulin manages diabetes rather than being a substitute vice.
Our directory lets you filter specifically for MAT-offering centers, and our MAT explained guide goes deeper on how each option fits into a broader treatment plan.